Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism

  • Clapper J
  • Moreno-Sanz G
  • Russo R
 et al. 
  • 192

    Readers

    Mendeley users who have this article in their library.
  • 180

    Citations

    Citations of this article.

Abstract

Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but the endocannabinoid signal that normally engages this intrinsic analgesic mechanism is unknown. To address this question, we developed a peripherally restricted inhibitor (URB937) of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of the endocannabinoid anandamide. URB937 suppressed FAAH activity and increased anandamide levels outside the rodent CNS. Despite its inability to access brain and spinal cord, URB937 attenuated behavioral responses indicative of persistent pain in rodent models of peripheral nerve injury and inflammation and prevented noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CB₁ cannabinoid receptor blockade prevented these effects. These results suggest that anandamide-mediated signaling at peripheral CB₁ receptors controls the access of pain-related inputs to the CNS. Brain-impenetrant FAAH inhibitors, which strengthen this gating mechanism, might offer a new approach to pain therapy.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Jason R. Clapper

  • Guillermo Moreno-Sanz

  • Roberto Russo

  • Ana Guijarro

  • Federica Vacondio

  • Andrea Duranti

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free